Effects of Aidi injection combined with XELOX chemotherapy regimen in treatment of patients with advanced colorectal cancer
Objective:To observe effects of Aidi injection combined with XELOX(Oxaliplatin+Capecitabine)chemotherapy regimen in treatment of patients with advanced colorectal cancer.Methods:A prospective study was conducted on 76 patients with advanced colorectal cancer admitted to this hospital from January 2022 to June 2023.According to the random number table method,they were divided into control group and study group,38 cases in each group.The control group was treated with XELOX chemotherapy regimen,while the study group was treated with Aidi injection on the basis of that of the control group.The clinical efficacy,the Karnofsky performance status(KPS)score,the tumor markers[carbohydrate antigen 72-4(CA72-4),carcinoembryonic antigen(CEA),carbohydrate antigen 242(CA242)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate of the study group was 63.16%(24/38),which was higher than 39.47%(15/38)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the KPS scores of the two groups were higher than those before the treatment,that in the study group was higher than that in the control group,and the differences were statistically significant(P<0.05).The levels of CA72-4,CEA and CA242 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the study group was 18.42%,which was lower than 42.11%in the control group,and the difference was statistically significant(P<0.05).Conclusions:Aidi injection combined with XELOX chemotherapy regimen in the treatment of the patients with advanced colorectal cancer can improve the disease control rate and the KPS scores,and reduce the levels of tumor markers and the incidence of adverse reactions.Moreover,it is superior to single XELOX chemotherapy.
NETL
NSTL
万方数据
